scholarly journals Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia

2019 ◽  
Vol 115 ◽  
pp. 17-23 ◽  
Author(s):  
Frédéric Millot ◽  
Natacha Maledon ◽  
Joelle Guilhot ◽  
Adalet Meral Güneş ◽  
Krzysztof Kalwak ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
De Novo ◽  
Favourable Outcome

scholarly journals Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase ‐ a comparison of clinical and genetic characteristics

2021 ◽  
Vol 193 (3) ◽  
pp. 613-618
Author(s):  
Stephanie Sembill ◽  
Gudrun Göhring ◽  
Elke Schirmer ◽  
Friederike Lutterloh ◽  
Meinolf Suttorp ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
De Novo ◽  
Blast Phase ◽  
Genetic Characteristics

Effects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid Leukaemia

2009 ◽  
Vol 37 (4) ◽  
pp. 1018-1028 ◽  
Author(s):  
M Sayitoglu ◽  
IC Haznedaroğlu ◽  
O Hatirnaz ◽  
Y Erbilgin ◽  
S Aksu ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Imatinib Mesylate ◽  
Kinase Inhibitors ◽  
De Novo ◽  
Renin Angiotensin System ◽  
Risk Groups ◽  
Mrna Levels ◽  
Angiotensin System ◽  
Renin Angiotensin

The renin–angiotensin system (RAS) is involved in cell growth, proliferation and differentiation in bone marrow in an autocrine–paracrine manner, and it modulates normal and neoplastic haematopoietic cell proliferation. This study aimed to assess expressions of the RAS components, renin, angiotensinogen and angiotensin-converting enzyme (ACE), during imatinib mesylate treatment of patients with chronic myeloid leukaemia (CML). Expressions of RAS components were studied in patients with CML at the time of diagnosis ( n = 83) and at 3, 6 and 12 months after diagnosis ( n = 35) by quantitative real-time polymerase chain reaction. De novo CML patients had increased ACE, angiotensinogen and renin mRNA levels and these expression levels decreased following administration of imatinib. The RAS activities were significantly different among Sokal risk groups of CML, highlighting the altered biological activity of RAS in neoplastic disorders. The results of this study confirm that haematopoietic RAS affects neoplastic cell production, which may be altered via administration of tyrosine kinase inhibitors such as imatinib mesylate.

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

Leukemia ◽  
2013 ◽  
Vol 28 (3) ◽  
pp. 702-705 ◽  
Author(s):  
C H Kok ◽  
T Leclercq ◽  
D B Watkins ◽  
V Saunders ◽  
J Wang ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
De Novo ◽  
Molecular Response

Haematological Disease Pattern at Specialized HOPD - A study in Bangabandhu Sheikh Mujib Medical University

2018 ◽  
Vol 2 (02) ◽  
pp. 39-41
Author(s):  
Md. Rafiquzzaman Khan ◽  
Arifur Rahman ◽  
Khaza Amirul Islam ◽  
AQM Ashraful Haque ◽  
Masuda Begum
Keyword(s):  
Iron Deficiency ◽  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Iron Deficiency Anaemia ◽  
Beta Thalassemia ◽  
Female Ratio ◽  
Deficiency Anaemia ◽  
Beta Thalassaemia ◽  
Hb E ◽  
Medical University

The aim of this retrospective observational study was to observe the pattern and frequency of haematological disorders among the patients attending in the specialized Haematology outpatient Department (HOPD) in Bangabandhu Sheikh Mujib Medical University. Consecutive 201 patients over the period of one year were enrolled. Their age ranged from 01 to 72 years with a mean age of 36.76 years. Most of the patients (34.3%) were in between the ages of 31 to 45 years followed by 16 to 30 years (27.9%). Male to female ratio was 0.65. Iron deficiency anaemia is the most common (24.9%) followed by chronic myeloid leukaemia (11.9%), Hb E beta thalassaemia (9.5%), idiopathic thrombocytopenic purpura (9.5%), beta thalassaemia trait (7.0%), Hb E trait (5.5 %), aplastic anaemia (5.0%), multiple myeloma (3.5%), acute lymphoblastic leukaemia (3.0%). Acute myeloid leukaemia, autoimmune haemolytic anaemia, chronic lymphocytic leukaemia, anaemia of chronic disease, non-Hodgkin lymphoma, polycythaemia, beta thalassemia major and alpha thalassemia was 2.5%, 2.5%, 2.0%, 1.5%, 1.5%, 1.5%, 1.0% and 1.0%, respectively. In the present study, we observed that iron deficiency anaemia the most common non-malignant disease and chronic myeloid leukaemia is the common haematological malignancy.

Chronic Myeloid Leukaemia

2017 ◽  
Vol 1 (01) ◽  
pp. 16-22
Author(s):  
Mohiuddin Ahmed Khan ◽  
Mafruh Akter ◽  
Muhammad Kamruzzaman
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia

2020 ◽  
Author(s):  
Simone Claudiani ◽  
Jane F. Apperley ◽  
Richard Szydlo ◽  
Afzal Khan ◽  
George Nesr ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Dose Reduction ◽  
Molecular Remission
Sign in / Sign up

Export Citation Format

Share Document